Welcome to our dedicated page for Spyre Therapeutics news (Ticker: SYRE), a resource for investors and traders seeking the latest updates and insights on Spyre Therapeutics stock.
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a clinical-stage biotechnology company developing long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The SYRE news page on Stock Titan aggregates company press releases, clinical updates, and capital markets announcements so readers can follow how Spyre’s programs and corporate activities evolve over time.
In its public communications, Spyre highlights a pipeline of investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23, with programs such as SPY001, SPY002, SPY072, and SPY003. News items frequently cover interim Phase 1 data, such as reports that SPY003 was well tolerated and exhibited an approximately 85-day half-life, and that SPY002 and SPY072 showed pharmacokinetic profiles supporting potential quarterly or twice-yearly maintenance dosing. Updates also describe the design and enrollment status of the SKYLINE Phase 2 platform trial in ulcerative colitis and the SKYWAY Phase 2 basket trial in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
Investors and followers of SYRE can also find announcements about stock offerings, use of proceeds, and equity inducement awards granted under the company’s equity plans, as well as participation in scientific congresses and investor conferences. Together, these news items provide insight into Spyre’s clinical development progress, financing activities, and broader corporate strategy as disclosed by the company.
For users tracking SYRE, this page offers a centralized view of Spyre Therapeutics’ official news flow, including trial milestones, interim study findings, and key financing events drawn from press releases and related disclosures.
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on Inflammatory Bowel Disease (IBD) treatment, has announced its participation in the Stifel 2024 Virtual Immunology and Inflammation Summit. The company's management will engage in a fireside chat on Wednesday, September 18, 2024, at 12:00 p.m. Eastern time.
Spyre Therapeutics specializes in antibody engineering, rational therapeutic combinations, and precision medicine approaches to improve IBD treatment efficacy and convenience. Investors and interested parties can access a webcast replay of the fireside chat on the company's investor events website for 90 days following the event.
Spyre Therapeutics (NASDAQ:SYRE) reported its Q2 2024 financial results and provided a corporate update. Key highlights include:
- Initiated Phase 1 trial of SPY001 (anti-α4β7 antibody) with interim data expected by year-end 2024
- SPY002 (anti-TL1A antibody) on track for first-in-human trials in H2 2024
- Nominated development candidate for SPY003 (anti-IL-23 antibody), with first-in-human trial expected in H1 2025
- $426 million in cash and equivalents as of June 30, 2024, with runway into 2027
- Q2 2024 R&D expenses: $32.6 million, up from $17.4 million in Q2 2023
- Q2 2024 net loss: $38.8 million, compared to $217.1 million in Q2 2023
The company is advancing its IBD pipeline with potentially best-in-class antibodies engineered for improved efficacy and convenience.
Spyre Therapeutics (NASDAQ: SYRE) announced the dosing of first participants in a Phase 1 trial for SPY001, a novel half-life extended anti-α4β7 antibody for treating Inflammatory Bowel Disease (IBD).
Preclinical data suggests improved dosing schedules, potentially every 8-12 weeks, compared to the standard biweekly dosing.
Interim pharmacokinetic and safety data are expected by year-end 2024.
Additionally, Spyre plans to begin first-in-human studies for SPY002, an anti-TL1A antibody, in the latter half of 2024.
All three targeted antibodies (α4β7, TL1A, IL-23) are expected to be in clinical trials within the next 12 months.
The Phase 1 trial will involve approximately 48 participants, focusing on safety and pharmacokinetics.
Spyre Therapeutics (NASDAQ: SYRE), a biotech firm focused on antibody engineering and precision medicine for Inflammatory Bowel Disease (IBD), announced the approval of stock options for 83,000 shares to three non-executive employees. These inducement awards were granted by Spyre's independent Compensation Committee under the 2018 Equity Inducement Plan. The options, approved on June 3, 2024, have a 10-year term with an exercise price of $36.79. They will vest and become exercisable gradually over four years, contingent on the employees' continuous service. This aligns with Nasdaq Listing Rule 5635(c)(4).
Spyre Therapeutics (NASDAQ: SYRE), a biotechnology company specializing in antibody engineering and precision medicine for Inflammatory Bowel Disease (IBD), will participate in the Jefferies Global Healthcare Conference. The event will feature a fireside chat and investor meetings on June 5, 2024, at 9:30 a.m. Eastern time. The webcast will be available on the Spyre website for 90 days post-conference.
Spyre Therapeutics (NASDAQ: SYRE) has appointed Dr. Sandra Milligan to its Board of Directors. Dr. Milligan, currently President of Aspira Women's Health, brings extensive experience in clinical development and regulatory affairs, particularly in Inflammatory Bowel Disease (IBD). Her expertise is expected to aid Spyre as they advance their antibody therapies targeting α4β7 and TL1A into clinical studies. Dr. Milligan will replace Russell Cox, whose term ended on May 13, 2024. Jeffrey Albers has been appointed Chairman of the Board in connection with Cox's departure.
Spyre Therapeutics, Inc. reported its first-quarter 2024 financial results and provided corporate updates. The company is advancing its anti-α4β7 antibody, SPY001, and anti-TL1A antibody, SPY002, towards first-in-human studies. With $485 million in cash and expected runway until 2027, Spyre is on track to achieve significant milestones in 2024 and beyond.
Spyre Therapeutics, Inc. announced the approval of grants of stock options to 4 non-executive employees as equity inducement awards. These options were granted under the 2018 Equity Inducement Plan with a 10-year term and an exercise price of $33.87 per share. The options will vest over time, subject to continuous service with Spyre.
Summary not available.
Summary not available.